Global Glioblastoma Multiforme Drugs Market US$ 890 Million by 2021

Global Glioblastoma Multiforme Drugs Market US$ 890 Million by 2021

Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive cancer that begins within the brain. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy. Typically, treatment involves surgery after which chemotherapy and radiation therapy is used. The medication temozolomide is frequently used as part of chemotherapy, whereas high dose steroids are used to help reduce swelling and decrease symptoms.

Glioblastoma Multiforme Drugs Market 2017-2021 report estimates the global Glioblastoma multiforme drugs market to reach nearly US$ 785 Million in 2020, at a CAGR of 13.4% from 2017 to 2021 – iHealthcareAnalyst, Inc.

Visit the Glioblastoma Multiforme Drugs Market 2017-2021 report https://www.ihealthcareanalyst.com/report/glioblastoma-multiforme-drugs-market/

The global Glioblastoma multiforme drugs market segmentation is based on drug types (Bevacizumab, Temozolomide, Carmustine). The global Glioblastoma multiforme drugs market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global Glioblastoma multiforme drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1.Drug Type
1.1 Bevacizumab (Avastin)
1.2 Temozolomide
1.3 Carmustine (BiCNU)

2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World

3. Company Profiles
3.1 AbbVie, Inc.
3.2 Activates GmbH
3.3 Agenus Inc.
3.4 Arog Pharmaceuticals, Inc.
3.5 Bristol-Myers Squibb Company
3.6 Cavion LLC
3.7 Celled Therapeutics Inc.
3.8 CTI BioPharma Corporation
3.9 Cortice Bioscience Inc.
3.10 Eisai Co., Ltd.
3.11 Exelixis Inc.
3.12 F.Hoffman-La Roche Ltd.
3.13 Peregrine Pharmaceuticals, Inc.
3.14 OncoSynergy
3.15 Merrimack Pharmaceuticals, Inc.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2017-11-05T09:55:14+00:00 Categories: Press Releases|